| 20/04/2024 |
07:40 to 09:35 |
Golden Hall |
Kidney Module - Localized Disease Session |
08:45 to 09:05 |
Adjuvant treatment with immunotherapy of high-risk kidney cancer for recurrence: are we finally reaching a consensus? |
Speaker |
| 20/04/2024 |
07:40 to 09:35 |
Golden Hall |
Kidney Module - Localized Disease Session |
09:05 to 09:10 |
Discussion |
Discussant |
| 20/04/2024 |
10:50 to 11:30 |
Golden Hall |
Clinical cases: localized kidney cancer |
|
|
Discussant |
| 20/04/2024 |
11:55 to 13:10 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
11:55 to 12:15 |
Optimizing first-line treatment for clear cell renal cell carcinoma: are we making important advances? |
Speaker |
| 20/04/2024 |
11:55 to 13:10 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
12:15 to 12:20 |
Discussion |
Discussant |
| 20/04/2024 |
11:55 to 13:10 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
12:45 to 13:05 |
Selection of second-line and onward treatment in advanced kidney cancer: what do studies say? |
Speaker |
| 20/04/2024 |
11:55 to 13:10 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
13:05 to 13:10 |
Discussion |
Discussant |
| 20/04/2024 |
13:35 to 14:00 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
13:35 to 13:55 |
New agents in the treatment of advanced kidney cancer: are there any ready to be used in clinical practice? |
Speaker |
| 20/04/2024 |
13:35 to 14:00 |
Golden Hall |
Kidney Module - Metastatic Disease Session |
13:55 to 14:00 |
Discussion |
Discussant |
| 20/04/2024 |
14:00 to 14:40 |
Golden Hall |
Clinical cases: metastatic kidney cancer |
|
|
Discussant |
